Physician profile
Daniel N Brown
NPI 1194826602
$6,733.32
in general payments reported to CMS, 2019-2025
17 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $857 · 2023: $2,434 · 2024: $1,876 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,631.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,727.25 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,599.10 | 2021-2025 | Biktarvy, Yeztugo |
| Janssen Biotech, INC. | $502.96 | 2021-2023 | Symtuza, Prezcobix |
| Janssen Products, LP | $377.89 | 2021-2023 | Symtuza |
| Hologic Sales and Service, LLC | $341.27 | 2023-2025 | Aptima |
| Theratechnologies INC. | $337.94 | 2022-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Emd Serono, INC. | $327.64 | 2023-2025 | Serostim |
| Madrigal Pharmaceuticals | $145.62 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $135.23 | 2023-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $55.41 | 2024-2025 | |
| Glaxosmithkline, LLC. | $44.36 | 2022-2024 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Novavax INC | $27.76 | 2024 | Novavax Covid-19 Vaccine, Adjuvanted |
| Lilly USA, LLC | $27.32 | 2024 | Zepbound, Mounjaro |
| Verity Pharmaceuticals INC. | $23.91 | 2024 | Tlando |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $20.72 | 2025 | Mytesi |
| Dynavax Technologies Corporation | $10.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.